Skip to content

EFFICACY OF DEXMEDETOMIDINE VERSUS MAGNESIUM SULPHATE AND LIGNOCAINE IN LARYNGOSCOPY AND INTUBATION RESPONSE AND COMPARE THEM WITH OPIOID ANAESTHESIA

TO EVALUATE AND COMPARE HEMODYNAMIC RESPONSE AND EFFICACY OF DEXMEDETOMIDINE VERSUS MAGNESIUM SULPHATE AND LIGNOCAINE IN PROVIDING OPIOID FREE GENERAL ANAESTHESIA

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/01/039528
Enrollment
150
Registered
2022-01-18
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K800- Calculus of gallbladder with acutecholecystitis

Interventions

Intervention1: DEXMEDETOMIDINE: Iv infusion of 0.75 mcg/kg DEXMEDETOMIDINE in 0.9%NS 20ml will be started 10mins before intubation and 4 ml NS for intubation Intervention2: Magnesium sulphate and Lign

Sponsors

Akanksha Sharma
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: ASA physical status I & II

Exclusion criteria

Exclusion criteria: 1. Pts with H/O uncontrolled HTN or hypotension 2. Bradycardia 3. Heart blocks 4. Pt with Cardiovascular disease 5. Allergies to any studies 6. BMI >30 kg/m2 7. Pts with more than one intubation attempt 8. Pts who refuse to give consent

Design outcomes

Primary

MeasureTime frame
To compare the effect of opioid free anaesthesia with opioid based anaesthesia on hemodynamic profile HR,SBP,DBP,MAP,SpO2,any otherTimepoint: Pre-infusion Pre-induction Baseline 1 min 5min 3 min 5 min 7 min 10 min 20 min 30 min

Secondary

MeasureTime frame
Post op vital monitoring Post op analgesia Post op nausea , vomiting, sedation Any complicationTimepoint: 0min 5min 10min 20min 30min 1hr 2hr 3hr

Countries

India

Contacts

Public ContactDr Akanksha Sharma

Indira Gandhi Medical College , Shimla

drmkpanwar@gmail.com9418086876

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026